AstraZeneca Tries Plan B For Dato-DXd After Regulator Feedback

 
• By Andrew McConaghie
  
AZ is looking for a narrower indication for its lung cancer candidate after withdrawing its initial FDA application. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Review Pathways

More from Pathways & Standards